This study is looking at the real-world experiences of people taking BRIUMVI® (ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS). Researchers want to understand how safe and effective BRIUMVI® is, and what it's like for patients to use it in their daily lives. You can join if you have a confirmed diagnosis of Multiple Sclerosis (MS) and have not yet received BRIUMVI®, or are about to start your first dose. The main goal is to measure the Annualized Relapse Rate (ARR), which is how often relapses happen in a year, for up to 96 weeks. The study is currently unclear on its recruitment status and aims to enroll 2000 participants.

Study design

This is an observational study, meaning researchers will watch and collect information about participants' experiences. It aims to include 2000 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track the Annualized Relapse Rate for up to 96 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.